MedTrace Logo

Evaluation of Succinate Metoprolol on Heart Rate in the Stable Angina Patients

NCT01213173 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 251

Last updated 2014-09-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the effects of Succinate Metoprolol(Betaloc ZOK®) (95 - 190 mg) on heart rate in the Stable angina patients.

Conditions

  • Angina Pectoris

Interventions

DRUG

Succinate Metoprolol (Betaloc ZOK®)

treatment with 47.5mg for two weeks, if tolerated and without Systolic blood pressure\<100mmHg and heart rate \<45 bpm according to 12-lead Electrocardiogram at Week 3, the dosage will be titrated to 95mg and last for another 6 weeks

DRUG

Succinate Metoprolol (Betaloc ZOK®)

Treatment with 95mg for two weeks, and if tolerated and without bradycardia symptoms presented, Systolic blood pressure\<100mmHg and heart rate \<45 bpm according to 12-lead Electrocardiogram at Week 3，the dosage will be force titrated to 190mg and last for another 6 weeks

Sponsors & Collaborators

Principal Investigators

  • Huo Yong · Department of Cardiology, Peking University First Hospital

  • Helen Lin · Astrazeneca China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01213173 on ClinicalTrials.gov